![](/img/cover-not-exists.png)
Risk of hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients with myeloproliferative neoplasms treated with ruxolitinib
Garcia-Horton, Alejandro, Smith, Elliot, Maze, Dawn, McNamara, Caroline, Sibai, Hassan, Gupta, VikasJournal:
Leukemia & Lymphoma
DOI:
10.1080/10428194.2020.1832671
Date:
October, 2020
File:
PDF, 754 KB
2020